Navigation Links
Transplant Head Honcho forced to dismount

The Abdominal Transplant Program, beset with administrative problems, experienced another upheaval. In a recent statement, The UCSD communicated its decision to relieve // Dr. Hart, the Director of the program for liver and kidney transplants, of his administrative responsibilities. Notwithstanding, Dr Hart will still continue as a full-time surgeon and member of the University's transplant team.

The UC San Diego, disappointed with the manner in which Dr Marquis Hart had conducted the UC Irvine’s Liver program, perceived to have misled organ officials, instigated his exit. Dr Marquis Hart had been offering part time services to the UCI since 2002 till the fall of 2005. During his tenure, The UCI liver program suffered huge setbacks prompting its closure.

Federal officials said that though the UCI was given 122 livers between 2004 and 2005, only 12 transplantations had occurred, a record low for any such program in the state. The UCI also did not have its own team of surgeons and therefore had to avail the services of Marquis and another UCSD surgeon. Further, Medicare also decided to cancel the payment for UCI’s Liver transplants.

Dr Hart was also part of a contract that allowed him to be a consultant surgeon for the UCI. The financial contract, according to Dr Thomas MacAfee, was between the UC Irvine and The UCSD Department of Surgery, and confirmed that the UCSD was not in the eye of any mischief or allegations. In the UCSD statement, the Chief Executive Officer, Richard Liekweg has reiterated that this is not a slur on the Doctor’s skill and commitment to his work. Infact, Dr Hart is regarded as an outstanding surgeon, deeply committed to his patients.

'"/>




Page: 1

Related medicine news :

1. Stem Cell Transplants May Be Effective For MS Patients
2. Drugs Deter Heart Disease for Transplant Patients
3. Better Drug for Heart Transplant
4. Kidney Failure after Non-Kidney Transplants
5. Measles Risk in Transplant Patients
6. Transplants Help Liver Cancer Patients
7. Steroid-Free Liver Transplants
8. Pancreas Transplant for Diabetics
9. Reducing The Risk Of Fractures After a Heart Transplant
10. A Urine Test Could Predict Rejection In Transplant Patients
11. Thawed Ovarian Transplant
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/18/2017)... ... August 18, 2017 , ... ... LLC (“Quick”), a highly specialized asset-light logistics provider of complex transport solutions ... definitive agreement to purchase Unitrans International Corporation, a division of Roadrunner Transportation ...
(Date:8/18/2017)... ... August 18, 2017 , ... As an ... an educational webinar, they will present the line of epMotion automated liquid handling ... easy you can automate everyday pipetting tasks. , Ideal for scientists and lab ...
(Date:8/18/2017)... ... August 18, 2017 , ... Moore Insurance, a Houston ... east Texas, is launching a regional charity effort to provide publicity assistance and ... Pediatric Brain Tumor Foundation (PBTF) has raised nearly $30 million in donations that ...
(Date:8/18/2017)... ... August 18, 2017 , ... The Golseth Agency, a Texas based ... area, is spearheading a regional charity campaign organized to provide support to Christina Upchurch ... of this year, Christina and her children returned from out of town to find ...
(Date:8/18/2017)... ... August 18, 2017 , ... Alcovit, a lime-flavored beverage that rids the ... efforts with its product now available through Jet.com. , After 25 years of ... powdered drink is designed to quickly detox the body thereby avoiding alcohol-induced hangovers. Whether ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... 15, 2017 AccuGenomics, Inc., a diagnostic company ... announced that the company has provided an AccuKit to ... Carolina at Chapel Hill and to Qura Therapeutics for ... and quantify HIV reservoir and viral expression in human ... HIV Cure Center is a joint initiative between the ...
(Date:8/8/2017)... Israel, Aug. 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), ... today reports its financial results for the second quarter ... during the second quarter 2017 and to date: ... clinical development programs for the Company,s lead project, BL-8040: ... pivotal study with BL-8040 as novel stem cell mobilization ...
(Date:8/7/2017)... 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation,s largest ... June 30, 2017.  All comparisons, unless otherwise noted, are to ... Second Quarter 2017 Highlights include: ... an increase of 3.5% Total prescriptions dispensed ... of 7.5% versus 7.6% Gross profit ...
Breaking Medicine Technology: